AR121836A1 - Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e - Google Patents

Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Info

Publication number
AR121836A1
AR121836A1 ARP210100979A ARP210100979A AR121836A1 AR 121836 A1 AR121836 A1 AR 121836A1 AR P210100979 A ARP210100979 A AR P210100979A AR P210100979 A ARP210100979 A AR P210100979A AR 121836 A1 AR121836 A1 AR 121836A1
Authority
AR
Argentina
Prior art keywords
hepatitis
nucleoside analogs
treatment
monocyclic nucleoside
monocyclic
Prior art date
Application number
ARP210100979A
Other languages
English (en)
Spanish (es)
Inventor
Tim Hugo Maria Jonckers
Frederik Pauwels
Yannick Debing
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of AR121836A1 publication Critical patent/AR121836A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ARP210100979A 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e AR121836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14

Publications (1)

Publication Number Publication Date
AR121836A1 true AR121836A1 (es) 2022-07-13

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100979A AR121836A1 (es) 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US9603864B2 (en) * 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
AU2021255809B2 (en) 2026-08-06
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
UY38059A (es) Heterociclos sustituidos como agentes antivirales
PE20190910A1 (es) Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
CO2021008055A2 (es) Heterociclos funcionalizados como agentes antivirales
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CR20240405A (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos.
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
DOP2022000171A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
CL2023003751A1 (es) Compuestos moduladores de diacilglicerol quinasa
UY37997A (es) Agentes antivirales contra la hepatitis b
UY37998A (es) Agentes antivirales contra la hepatitis b
CR20210664A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CL2023002074A1 (es) Compuestos de piridotriazina sustituidos y usos de estos
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CR20220085A (es) Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones
CL2022003400A1 (es) Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette
MX2023011552A (es) Compuestos de 1-arilo-1'-heteroarilo sustituido, compuestos de 1,1'-biheteroarilo sustituido, y métodos de uso de estos.
CL2022002804A1 (es) Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e.
MX2025010886A (es) Nuevo compuesto, y una composicion farmaceutica para la prevencion o el tratamiento del cancer o tumores que comprende el mismo
PE20230559A1 (es) Medicamentos antivirales para el tratamiento y prevencion de la infeccion por vih
BR112022020810A2 (pt) Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e
BR112022020820A2 (pt) Análogos de nucleosídeos alquinílicos para o tratamento de hepatite e
AR127582A1 (es) Métodos para el tratamiento del cáncer